Skip to main content
Premium Trial:

Request an Annual Quote

ActivX Biosciences, Kyorin Pharmaceutical To Develop Diabetes Drugs

NEW YORK, June 4-ActivX Biosciences has inked a deal with Tokyo's Kyorin Pharmaceutical company to identify and optimize new drugs for type II diabetes, the company said today.

 

ActivX, which studies protein activity in disease, will develop assays, screen and profile hit and lead compounds. Kyorin will provide the company with research support, milestone payments, and royalties on any commercialized products. ActivX also retains rights for some compounds that may be active in other diseases.

 

Kyorin will conduct medicinal chemistry, animal pharmacology and clinical development on lead compounds. The company has worldwide manufacturing and marketing rights to any drugs developed in the collaboration.

 

ActivX is the Japanese pharmaceutical company's first U.S. biotechnology partner.

 

Based in La Jolla, ActivX studies disease mechanisms by analyzing protein activity.

 

For further details, read the press release.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.